We received FDA Breakthrough Therapy designation in 2018 for our COMP360 psilocybin for TRD. In late 2021, we completed a randomised, controlled, double-blind phase IIb study of COMP360 psilocybin therapy in 233 patients with TRD in 22 sites across Europe and North America.
We announced topline data from this trial in November 2021.
Learn about our phase IIb study results
We are working as quickly as we can to develop psilocybin therapy for people suffering with TRD, and plan to begin our phase III programme in 2022.
Treatment-resistant depression study
The map below shows the sites for our phase IIb clinical trial. The numbers on the map indicate the number of centres in that location. This trial has been completed and participants are no longer being recruited.
We will update this map with the sites that will be involved in our phase III trial once they have been approved. This is likely to be in mid-2022.
COMPASS does not control and is not responsible for the content on the website you may visit by clicking on the links in the map above. COMPASS is providing these links as a convenience, and these links do not imply COMPASS endorsement of any material on the websites you may visit.
We are keen to progress research that has the potential to change mental health outcomes.
Accessibility options
